|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
L Volin, V Rasi, E Vahtera and R Tenhunen
Third Department of Medicine, University of Helsinki, Finland.
Hematin, the drug used for acute porphyric attacks, has been shown to cause
disturbances in hemostasis, mainly because of its degradation products.
Lately a new heme compound, heme arginate, has been developed for the
treatment of porphyrias. In experimental animal studies as well as in
clinical use it has proved to be well tolerated. To find out whether heme
arginate has any effects on hemostasis we have studied a number of
parameters of coagulation and fibrinolysis after a heme arginate infusion
in seven healthy volunteers. All parameters studied remained practically
unchanged except the coagulation factor X, which showed a transient,
insignificant decrease during the maximal heme concentration. We believe
that the lack of side effects is due to a better stability of heme
arginate, the degradation rates being 1% for heme arginate and 61% for
hematin in four hours. Our data favor the use of heme arginate in acute
porphyrias as well as in other deficiency states of heme.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1988 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
